MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Balance Sheets Overview
Current Ratio
4.99%
Quick Ratio
4.99%
Debt to Asset Ratio
2002.97%
Unit: Dollar
Assets Breakdown
Prepaid expenses and other curre...
Cash
Liabilities Breakdown
Accumulated deficit
Additional paid-in-capital
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Vendor deposits
-
14,484
169,363
98,234
Cash
302,660
101,778
527,978
72,086
Prepaid expenses and other current assets
439,563
231,639
298,192
378,749
Total current assets
742,223
347,901
995,533
549,069
Vendor deposit
-
-
-
69,477
In-process research and development
-
-
-
18,647,903
Deferred offering costs
-
-
44,727
374,662
Total assets
742,223
347,901
1,040,260
19,641,111
Accounts payable
10,235,276
10,123,391
9,805,129
9,774,230
Accrued expenses and other current liabilities
3,303,242
2,611,296
2,960,698
2,915,448
Convertible notes payable at fair value
1,200,000
-
-
-
Warrant liabilities
128,000
-
-
-
Total current liabilities
14,866,518
12,734,687
12,765,827
12,689,678
Deferred tax liability
-
-
-
851,659
Total liabilities
14,866,518
12,734,687
12,765,827
13,541,337
Preferred stock
1
1
1
1
Preferred stock-Series APreferred Stock
-
-
-
0
Common stock
809
809
809
487
Additional paid-in-capital
125,260,381
125,204,509
125,187,156
123,207,260
Accumulated deficit
-139,378,318
-137,584,937
-136,906,365
-117,100,806
Treasury stock, at cost, 7 shares at march 31, 2026 and december 31, 2025
7,168
7,168
7,168
7,168
Total stockholders deficit
-14,124,295
-12,386,786
-11,725,567
6,099,774
Total liabilities and stockholders deficit
742,223
347,901
1,040,260
19,641,111
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Prepaid expenses and
other current assets
$439,563
Cash
$302,660
Total current assets
$742,223
Total assets
$742,223
Accumulated deficit
-$139,378,318
Treasury stock, at cost, 7
shares at march 31, 2026...
$7,168
Total liabilities and
stockholders deficit
$742,223
Total stockholders
deficit
-$14,124,295
Additional
paid-in-capital
$125,260,381
Common stock
$809
Preferred stock
$1
Total liabilities
$14,866,518
Total current
liabilities
$14,866,518
Accounts payable
$10,235,276
Accrued expenses and
other current...
$3,303,242
Convertible notes payable at
fair value
$1,200,000
Warrant liabilities
$128,000
Buy us a coffee
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)